{"id":"yellow-fever-vaccine-yfv","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Headache"},{"rate":"10–30","effect":"Myalgia"},{"rate":"5–15","effect":"Fever"},{"rate":"5–15","effect":"Injection site reaction (pain, erythema, swelling)"},{"rate":"5–10","effect":"Fatigue"},{"rate":"0.3–0.4 per 100,000 doses","effect":"Yellow fever vaccine-associated viscerotropic disease (YEL-AVD)"},{"rate":"0.4–1.3 per 100,000 doses","effect":"Yellow fever vaccine-associated neurotropic disease (YEL-AND)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"YFV contains a weakened live yellow fever virus (17D strain) that replicates in vaccinated individuals without causing disease, triggering both humoral (antibody) and cell-mediated immune responses. This generates protective immunity against natural yellow fever virus infection, with neutralizing antibodies typically appearing within 7–10 days and lasting for decades or life.","oneSentence":"Yellow fever vaccine stimulates the immune system to produce antibodies and cellular immunity against yellow fever virus through a live attenuated viral strain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:29.896Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic countries"}]},"trialDetails":[{"nctId":"NCT02743455","phase":"PHASE1","title":"A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-07-05","conditions":"Yellow Fever, Yellow Fever Immunisation","enrollment":92},{"nctId":"NCT06399003","phase":"PHASE3","title":"Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2024-06-28","conditions":"Measles-Mumps-Rubella","enrollment":1200},{"nctId":"NCT05172544","phase":"PHASE1","title":"Trial of an Inactivated Yellow Fever Virus Vaccine","status":"COMPLETED","sponsor":"Najit Technologies, Inc.","startDate":"2022-01-13","conditions":"Yellow Fever","enrollment":26},{"nctId":"NCT05801978","phase":"PHASE4","title":"Durability of Vaccine Responses","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-04-11","conditions":"Vaccine Response","enrollment":66},{"nctId":"NCT05421611","phase":"PHASE3","title":"A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2023-05-11","conditions":"Yellow Fever","enrollment":1824},{"nctId":"NCT02963909","phase":"PHASE1","title":"A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-11-01","conditions":"Zika Virus Infection","enrollment":75},{"nctId":"NCT05447377","phase":"PHASE3","title":"A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants","status":"UNKNOWN","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2022-09-16","conditions":"Yellow Fever","enrollment":2216},{"nctId":"NCT05332197","phase":"PHASE3","title":"Booster Vaccine for Yellow Fever","status":"UNKNOWN","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2022-05-16","conditions":"Yellow Fever","enrollment":750},{"nctId":"NCT03776786","phase":"PHASE1","title":"Safety and Tolerability of an Antibody Against Yellow Fever Virus (TY014) in Humans","status":"COMPLETED","sponsor":"Tysana Pte Ltd","startDate":"2018-12-06","conditions":"Treatment of Acute Yellow Fever Virus Infection","enrollment":37},{"nctId":"NCT03541694","phase":"","title":"Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-11","conditions":"Yellow Fever","enrollment":622},{"nctId":"NCT02286895","phase":"PHASE4","title":"Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali","status":"COMPLETED","sponsor":"PATH","startDate":"2014-10","conditions":"Diarrhea Rotavirus","enrollment":600},{"nctId":"NCT00995865","phase":"PHASE1","title":"Trial of Yellow Fever Inactivated Vaccine","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2010-01","conditions":"Yellow Fever","enrollment":60},{"nctId":"NCT00254826","phase":"PHASE1","title":"Yellow Fever Virus Vaccine and Immune Globulin Study","status":"COMPLETED","sponsor":"Emory University","startDate":"2006-06","conditions":"Viremia","enrollment":80},{"nctId":"NCT00982137","phase":"PHASE2","title":"Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-07","conditions":"Japanese Encephalitis, Yellow Fever","enrollment":108}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"yellow fever vaccine (YFV)","genericName":"yellow fever vaccine (YFV)","companyName":"PATH","companyId":"path","modality":"Biologic","firstApprovalDate":"","aiSummary":"Yellow fever vaccine stimulates the immune system to produce antibodies and cellular immunity against yellow fever virus through a live attenuated viral strain. Used for Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic countries.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}